All Stories

  1. Plasma biomarkers in neuropsychiatric syndromes: A narrative review
  2. Disentangling the Clinical and Neuroimaging Spectrum of Neuronal α-Synucleinopathies
  3. Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co‐pathologies, and sex differences
  4. Message From the Editors to Our Reviewers
  5. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  6. APOE -mediated associations of promoter variants of GRIN1 and GRIN2B with behavioral symptoms and age at onset of Alzheimer’s disease dementia
  7. Understanding barriers and optimizing socio‐cognitive assessment in the diagnosis of neurocognitive disorders
  8. Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
  9. Message From the Editors to Our Reviewers
  10. The problem of multiple adjustments in the assessment of minimal clinically important differences
  11. Biomarkers in Clinical Trials of Alzheimer Disease: An Overview
  12. Associations between selected genetic variants and lipid profile variability in response to statins in Alzheimer’s disease: a prospective observational study
  13. List of Reviewers
  14. Anthropometric and Demographic Features Affect the Interpretation of Cerebrospinal Fluid Biomarkers in Patients with Different Dementia Syndromes and Cognitively Healthy Adults
  15. Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
  16. Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
  17. Assessing Independence in Activities of Daily Living and Quality of Life in Patients with Dementia with Lewy Bodies
  18. Message From the Editors to Our Reviewers
  19. Shedding Light on the Effects of Blood Pressure on Cognitive Decline and Dementia Risk by Way of Neurobiological Evidence
  20. Biofluid Activity and Levels of the Angiotensin-converting Enzyme Are Surrogates for Diverse Cerebrospinal Fluid Amyloid-beta Effects in Dementia with Lewy Bodies and Alzheimer’s Dementia (P6-9.001)
  21. Message From the Editors to Our Reviewers
  22. Acknowledgement to Reviewers
  23. List of Reviewers
  24. GRIN2B genotypes and APOE haplotypes affect the age at onset of Alzheimer’s dementia as well as variations in dementia staging according to the use of Memantine
  25. Differential performance of cerebrospinal fluid biomarker ratios and formulas to discriminate dementia with Lewy bodies from Alzheimer’s dementia and cognitively healthy people reflects high level of amyloidosis across dementia syndromes
  26. Biofluid activity and levels of the angiotensin‐converting enzyme may translate into distinct neuropsychiatric symptoms associated with cerebrospinal fluid amyloid‐beta effects and tauopathy in dementia with Lewy bodies and Alzheimer’s dementia
  27. Disparities in neuropsychiatric symptom clusters across dementia diagnoses within Lewy body dementia syndromes and Alzheimer’s dementia
  28. Variations in metabolic risk factors for dementia do not affect APOE‐mediated cognitive or functional decline in patients with Alzheimer’s disease from São Paulo, Brazil
  29. Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions
  30. Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer’s disease
  31. Message From the Editors to Our Reviewers
  32. Looking Behind the Curtain: Patient Stratification According to Genetic or Demographic Factors May Yield Unexpected Results in Studies of Neurodegenerative Diseases
  33. Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer’s Disease at the Memory Clinic: The BEAT-IT Study
  34. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer’s disease
  35. Lifestyle and pharmacological interventions in South America: Potential barriers for recruitment, implementation, and effectiveness
  36. Acknowledgement to Reviewers
  37. Message From the Editors to Our Reviewers
  38. List of Reviewers
  39. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
  40. Acknowledgement to Referees
  41. Acknowledgement
  42. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer’s Disease
  43. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
  44. Message From the Editors to Our Reviewers
  45. Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease
  46. New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
  47. The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer’s Disease
  48. Vascular cognitive impairment and dementia: An early career researcher perspective
  49. Message From the Editors to Our Reviewers
  50. List of Reviewers
  51. Acknowledgement
  52. Reviewer Acknowledgement, 2021
  53. Message From the Editors to Our Reviewers
  54. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People
  55. Abstract Anne H Berman – incoming ISBM president
  56. Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer’s disease depend upon stratification according to APOE-ϵ4 carrier status
  57. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe
  58. APOE-ɛ4-mediated correlates of cerebrospinal fluid biomarkers of amyloidosis and neurodegeneration with cognition and functionality in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (49)
  59. Acknowledgements to Reviewers
  60. Swallowing in behavioral variant frontotemporal dementia
  61. Message From the Editors to Our Reviewers
  62. List of Reviewers
  63. Klüver‐Bucy syndrome due to stroke in the left temporal lobe
  64. Vascular cognitive impairment due to dilated perivascular spaces in putamen: Connections with the ventrolateral prefrontal cortex and neurological deficits
  65. Dementia in Latin America: Paving the way toward a regional action plan
  66. Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia
  67. Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
  68. Neuropsychiatric feature profiles of patients with Lewy body dementia
  69. Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
  70. The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
  71. Acknowledgments
  72. CEREBROSPINAL-FLUID-BASED BIOMARKER EVIDENCE OF AMYLOIDOGENESIS IN DEMENTIA WITH LEWY BODIES DEPENDS UPON APOE-ε4 CARRIER STATUS
  73. PRISON WITHOUT WALLS: A CASE REPORT OF SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA
  74. GRIN2A GENOTYPES AND APOE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER’S DEMENTIA BUT NOT FUNCTIONAL OR COGNITIVE RESPONSE TO MEMANTINE
  75. FOOT CLEARANCE WHILE STEPPING-IN-PLACE AS A TOOL TO SALIENT COGNITIVE AND MOTOR OUTPUT DEFICITS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A PRELIMINARY STUDY
  76. BEHAVIORAL CORRELATES OF CEREBROSPINAL FLUID BIOMARKERS ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  77. Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
  78. Acknowledgements to Reviewers
  79. Acknowledgments
  80. Influence of Socioeconomic Status and Stress Over Quality of Sleep: A Systematic Review
  81. Author Index
  82. Keyword Index
  83. Movement Disorders: Volume 33, Number S2, October 2018
  84. Abstracts
  85. Lifetime Risk Factors for Functional and Cognitive Outcomes in Patients with Alzheimer’s Disease
  86. GENETICALLY MEDIATED LIFETIME RISK FACTORS FOR COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH ALZHEIMER’S DEMENTIA FROM SÃO PAULO, BRAZIL
  87. APOE-DEPENDENT PSYCHOTROPIC EFFECTS OVER CLINICAL CHANGES IN ALZHEIMER’S DISEASE DEMENTIA
  88. COGNITIVE AND FUNCTIONAL CORRELATES OF CEREBROSPINAL FLUID CONCENTRATIONS OF AMINOACIDS AND MONOAMINE METABOLITES ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  89. COGNITIVE CHANGES ARE PHARMACOGENETICALLY MEDIATED BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH ALZHEIMER’S DISEASE DEMENTIA
  90. Behavioral correlates of cerebrospinal fluid concentrations of aminoacids and monoamine metabolites according to APOE-ɛ4 carrier status in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (P4.190)
  91. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
  92. Acknowledgement to reviewers
  93. Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease
  94. Acknowledgements to Reviewers
  95. ePresentation
  96. ePoster Session
  97. Author Index
  98. Issue Information
  99. Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia
  100. Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
  101. Reviewers for International Journal of Stroke 2016
  102. Neurological impressions on the organization of language networks in the human brain
  103. GRIN1 GENOTYPES AND APOE GENE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER'S DISEASE DEMENTIA BUT NOT COGNITIVE OR FUNCTIONAL RESPONSE TO MEMANTINE
  104. EFFECTS OF APOE GENE HAPLOTYPES AND MEASURES OF CARDIOVASCULAR RISK OVER COGNITIVE AND FUNCTIONAL DECLINE IN ONE YEAR IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
  105. MOTOR ASPECTS OF DAILY LIVING FOLLOW COGNITIVE AND FUNCTIONAL STATUS BUT NOT BEHAVIOURAL SYMPTOMS IN PATIENTS WITH LEWY BODY DEMENTIA SYNDROMES
  106. Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
  107. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease
  108. Swallowing in primary progressive aphasia
  109. Predictors of Cognitive and Functional Decline in Patients With Alzheimer Disease Dementia From Brazil
  110. Associations of Blood Pressure with Functional and Cognitive Changes in Patients with Alzheimer's Disease
  111. The Controversial Influence of Cerebrovascular Risk Factors over Pathological Mechanisms of Late-Onset Alzheimer's Disease Dementia
  112. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil
  113. Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease
  114. Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia
  115. A patient with agrammatic primary progressive aphasia developing frontotemporal dementia
  116. Pharmacogenetics of cerebrovascular metabolism modulators in dementia due to Alzheimer’s disease
  117. Assessment of sleep satisfaction in patients with dementia due to Alzheimer’s disease
  118. Acknowledgements
  119. Is there correlation between cognition and functionality in severe dementia? The value of a performance-based ecological assessment for Alzheimer’s disease
  120. Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease
  121. P2‐024: PHARMACOGENETICS OF BRAIN‐PENETRATING ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS IN DEMENTIA DUE TO ALZHEIMER'S DISEASE
  122. P2‐025: PHARMACOGENETICS OF CHOLESTEROL‐LOWERING DRUGS IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE
  123. P3‐333: RISK FACTORS FOR COGNITIVE CHANGE IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE FROM SÃO PAULO, BRAZIL
  124. Caregiver awareness of cerebrovascular risk of patients with dementia due to Alzheimer's disease in São Paulo, Brazil
  125. Abstracts from the 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada, 22–26 June 2014
  126. Risk Factors for Cognitive Change in Patients with Dementia Due to Alzheimer’s Disease (P5.210)
  127. Pharmacogenetics of Lipid Metabolism Modulators in Patients with Dementia Due to Alzheimer’s Disease (P5.223)
  128. Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil
  129. 2013 Reviewer Acknowledgement
  130. Assessment of risk factors for earlier onset of sporadic Alzheimer′s disease dementia
  131. Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe Mini-Mental State Examination
  132. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
  133. Cognitive Impairment in Fibromyalgia
  134. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (IN6-1.009)
  135. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (P07.136)
  136. Communicating with the non-dominant hemisphere: Implications for neurological rehabilitation
  137. Normal pressure hydrocephalus in the spectrum of neurological complications of systemic lupus erythematosus
  138. A patient with primary progressive aphasia developing dementia due to Alzheimer's disease
  139. Impact of Cerebrovascular Risk Factors over Age of Onset of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from Sao Paulo, Brazil (P04.201)
  140. 2012 Annual Meeting Sunday, October 7, 2012 Poster Session Abstracts
  141. A topographic study on the evaluation of speech and language in the acute phase of a first stroke
  142. P1‐453: Functional independence and tests of cognitive assessment in patients with Alzheimer's disease
  143. P2‐153: Impact of cardiovascular risk factors over age of Alzheimer's disease onset in patients with low schooling
  144. P3‐260: Impact of schooling and cardiovascular risk factors over the rate of progression of Alzheimer's disease
  145. Twenty-first Meeting of the European Neurological Society 28–31 May, 2011
  146. Global aphasia as a predictor of mortality in the acute phase of a first stroke
  147. Semantic aphasia as a sole manifestation of acute stroke
  148. Preliminary topographic diagnosis of ischemic brain injuries according to speech and language disorders
  149. Short-term prognosis for speech and language in first stroke patients
  150. Hypoglossal nerve palsy as the sole manifestation of spontaneous internal carotid artery dissection
  151. Author Index
  152. Abstracts
  153. 0661 Primitive Neuroectodermal Tumor of the brain presenting with late spinal cord dissemination after surgical treatment and complementary radiotherapy and chemotherapy
  154. 1499 Trends on the use of complementary exams in modern day neurology: how to teach the patient about the tools actually needed for the investigation without conflicting knowledge with popular wisdom